Patents by Inventor Yan-Ling Zhang
Yan-Ling Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9790184Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.Type: GrantFiled: July 29, 2013Date of Patent: October 17, 2017Assignees: The Broad Institute, Inc., The General Hospital CorporationInventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis, Tracey Lynn Petryshen
-
Publication number: 20170217955Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R1a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: ApplicationFiled: May 5, 2016Publication date: August 3, 2017Applicants: The Broad Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital, Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen J. Haggarty, Yan-Ling Zhang
-
Publication number: 20160347761Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: ApplicationFiled: August 11, 2016Publication date: December 1, 2016Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen J. Haggarty, Yan-Ling Zhang
-
Patent number: 9447030Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: GrantFiled: October 28, 2013Date of Patent: September 20, 2016Assignees: Massachusetts Institute of Technology, The General Hospital Corporation, The Broad Institute, Inc.Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen Haggarty, Yan-Ling Zhang
-
Publication number: 20160251351Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R1a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: ApplicationFiled: May 5, 2016Publication date: September 1, 2016Applicants: The Broad Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital, Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen J. Haggarty, Yan-Ling Zhang
-
Patent number: 9365498Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: GrantFiled: October 28, 2013Date of Patent: June 14, 2016Assignees: The Broad Institute, Inc., The General Hospital Corporation, Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen Haggarty, Yan-Ling Zhang
-
Publication number: 20150191427Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.Type: ApplicationFiled: July 29, 2013Publication date: July 9, 2015Applicants: The General Hospital Corporation d/b/a Massachusetts General Hospital, The Broad Institute, Inc.Inventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis
-
Publication number: 20140335550Abstract: The invention relates to a compound of Formula I: F1-X1-L1-X2-P1-X3-G1??(Formula I).Type: ApplicationFiled: May 1, 2014Publication date: November 13, 2014Applicant: The Broad Institute, Inc.Inventors: Yan-Ling Zhang, Edward Holson, Florence F. Wagner
-
Publication number: 20140080800Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: ApplicationFiled: October 28, 2013Publication date: March 20, 2014Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen Haggarty, Yan-Ling Zhang
-
Publication number: 20140080802Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: ApplicationFiled: October 28, 2013Publication date: March 20, 2014Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen Haggarty, Yan-Ling Zhang
-
Publication number: 20120264403Abstract: A communication control system includes an electronic device and a communication apparatus paired with the electronic device. The electronic device includes an input unit, a first BLUETOOTH unit, and a dialing control module. The input unit generates commands in response to operations of a user. The dialing control module generates dial information when a dialing command is received, and controls the first BLUETOOTH unit to transmit the dial information to the communication apparatus. The communication apparatus includes a wireless communication unit, a second BLUETOOTH unit, and a dialing module. The dialing module controls the wireless communication unit to dial according to the dial information. The dialing module also controls the second BLUETOOTH unit to transmit real-time dial information and voice signals of the user to the electronic device. A related method is also provided.Type: ApplicationFiled: July 26, 2011Publication date: October 18, 2012Applicants: HON HAI PRECISION INDUSTRY CO., LTD., HONG FU JIN PRECISION INDUSTRY (SHENZHEN) CO., LTD.Inventors: KUAN-HONG HSIEH, MING-TSUNG CHEN, HUI-FANG PENG, YAN-LING ZHANG
-
Patent number: 8071348Abstract: The present invention provides protein tyrosine phosphatases (PTP) in which the invariant aspartate residue and the invariant glutamine residue are each replaced with a replacement amino acid residue, wherein the replacement residues together cause a reduction in catalytic rate (kcat) of the enzyme and an increase in substrate-binding affinity (Kd) of the enzyme. The present invention further provides methods for identifying a substrate of a PTP. Also provided are kits for identifying a substrate of a PTP. Additionally, the present invention provides methods for identifying an agent that alters interaction between a PTP and a substrate of the PTP. The invention also provides methods for reducing the activity of a substrate of a PTP.Type: GrantFiled: January 10, 2003Date of Patent: December 6, 2011Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Zhong-Yin Zhang, Laiping Xie, Yan-Ling Zhang
-
Patent number: 7521473Abstract: Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted thiophene compounds such as, for example, 2-carboxyl, 3-carboxymethoxy, 5-aryl substituted thiophenes, can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.Type: GrantFiled: February 23, 2005Date of Patent: April 21, 2009Assignee: WyethInventors: Jinbo Lee, Zhao-Kui Wan, Douglas P. Wilson, Bruce C. Follows, Steven J. Kirincich, Michael J. Smith, Jun-Jun Wu, Kenneth W. Foreman, David V. Erbe, Yan-Ling Zhang, Weixin Xu, Steve Y. Tam
-
Publication number: 20090048286Abstract: Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted bicyclic fused-thiophene compounds can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.Type: ApplicationFiled: September 23, 2008Publication date: February 19, 2009Applicant: WyethInventors: Jinbo Lee, Steven J. Kirincich, Michael J. Smith, Douglas P. Wilson, Bruce C. Follows, Zhao-Kui Wan, Diane M. Joseph-McCarthy, David V. Erbe, Yan-Ling Zhang, Weixin Xu, Steve Y. Tam
-
Publication number: 20050203087Abstract: Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted thiophene compounds such as, for example, 2-carboxyl, 3-carboxymethoxy, 5-aryl substituted thiophenes, can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.Type: ApplicationFiled: February 23, 2005Publication date: September 15, 2005Inventors: Jinbo Lee, Zhao-Kui Wan, Douglas Wilson, Bruce Follows, Steven Kirincich, Michael Smith, Jun-Jun Wu, Kenneth Foreman, David Erbe, Yan-Ling Zhang, Weixin Xu, Steve Tam
-
Publication number: 20050203081Abstract: Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted bicyclic fused-thiophene compounds can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.Type: ApplicationFiled: February 23, 2005Publication date: September 15, 2005Inventors: Jinbo Lee, Steve Kirincich, Michael Smith, Douglas Wilson, Bruce Follows, Zhao-Kui Wan, Diane Joseph-McCarthy, David Erbe, Yan-Ling Zhang, Weixin Xu, Steve Tam
-
Publication number: 20030170855Abstract: The present invention provides protein tyrosine phosphatases (PTP) in which the invariant aspartate residue and the invariant glutamine residue are each replaced with a replacement amino acid residue, wherein the replacement residues together cause a reduction in catalytic rate (kcat) of the enzyme and an increase in substrate-binding affinity (Kd) of the enzyme. The present invention further provides methods for identifying a substrate of a PTP. Also provided are kits for identifying a substrate of a PTP. Additionally, the present invention provides methods for identifying an agent that alters interaction between a PTP and a substrate of the PTP. The invention also provides methods for reducing the activity of a substrate of a PTP.Type: ApplicationFiled: January 10, 2003Publication date: September 11, 2003Inventors: Zhong-Yin Zhang, Laiping Xie, Yan-Ling Zhang
-
Patent number: 5338670Abstract: A fermentation level cultivation of Bordetella pertussis bacteria on commercial scale is described. The critical factors in large scale cultivation of the bacteria are the presence of an antifoam agent and maintaining proper oxygen level and iron content in the culture medium. Pertussis toxin produced by the bacteria parallels the rate of growth of the bacteria.Type: GrantFiled: December 11, 1992Date of Patent: August 16, 1994Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Ronald D. Sekura, Yan-Ling Zhang, Joseph Shiloach